Tango Therapeutics
TNGX
21.83
-0.07
-0.32%
Tango Therapeutics
US · TNGX
#2322 by market cap
Listed 1970
21.83
-0.07
-0.32%
Live - 5344 symbols - heartbeat 365s ago
· 2026-10-08 06:07
Pre-market
21.69
-0.64%
After-hours
21.83
0.00%
- Market cap
- 3.68B
- P/E (TTM)i
- -25.99
- P/Bi
- 3.59
- EPSi
- -0.87
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on TNGX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 40.17, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +48.29% YoY
Margins
- Operating margin
- -178.39%
- Net margin
- -162.85%
Key ratios & quality
- Altman Z-Scorei
- 40.17
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.66M | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.87M | 17.60M | 30.03M | 35.50M | 43.75M | 41.51M |
| Research & development | 49.99M | 77.64M | 105.91M | 115.20M | 143.92M | 132.17M |
| Operating profit | -52.20M | -58.19M | -111.07M | -114.17M | -145.60M | -111.29M |
| Pretax profit | -51.97M | -57.94M | -108.12M | -101.61M | -130.09M | -101.59M |
| Tax | 0 | 292.00K | 54.00K | 134.00K | 208.00K | 4.00K |
| Net profit | -51.97M | -58.24M | -108.18M | -101.74M | -130.30M | -101.59M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.59 | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 5.39M | 3.18M | 53.81M | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.48M | 11.34M | 8.92M | 9.76M | 15.24M | 22.59M |
| Research & development | 36.44M | 32.81M | 30.82M | 32.10M | 33.53M | 37.20M |
| Operating profit | -42.53M | -40.97M | 14.07M | -41.86M | -48.77M | -59.79M |
| Pretax profit | -39.84M | -38.82M | 15.87M | -38.80M | -45.51M | -55.34M |
| Tax | 34.00K | 35.00K | -10.00K | -55.00K | 1.00K | 1.00K |
| Net profit | -39.88M | -38.85M | 15.88M | -38.75M | -45.51M | -55.34M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.36 | -0.35 | 0.13 | -0.29 | -0.32 | -0.37 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 193.63M | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M |
| Cash & ST investments | 190.32M | 485.26M | 366.13M | 336.89M | 257.92M | 343.14M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 207.25M | 500.16M | 436.47M | 402.57M | 316.49M | 398.69M |
| Total current liabilities | 40.92M | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
| Short-term debt | 959.00K | 1.50M | 1.77M | 2.08M | 2.45M | 2.74M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 168,652,000.00 | 155,408,000.00 | 186,994,000.00 | 149,459,000.00 | 116,975,000.00 | 52,511,000.00 |
| Total equity | 38.60M | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Retained earnings | -103.10M | -161.34M | -269.51M | -371.26M | -501.56M | -603.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 224.93M | 190.10M | 163.78M | 353.76M | 392.33M | 1.03B |
| Cash & ST investments | 216.72M | 180.79M | 152.81M | 343.14M | 379.84M | 1.01B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 274.31M | 237.89M | 210.14M | 398.69M | 435.79M | 1.07B |
| Total current liabilities | 35.92M | 40.03M | 18.44M | 21.68M | 14.33M | 20.30M |
| Short-term debt | 2.82M | 2.53M | 3.10M | 2.74M | 2.83M | 2.94M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 107,550,000.00 | 102,936,000.00 | 50,105,000.00 | 52,511,000.00 | 44,286,000.00 | 49,348,000.00 |
| Total equity | 166.76M | 134.95M | 160.03M | 346.18M | 391.51M | 1.02B |
| Retained earnings | -541.43M | -580.29M | -564.40M | -603.15M | -648.67M | -704.01M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 70.07M | -59.53M | -109.08M | -117.98M | -131.50M | -138.89M |
| Depreciation & amortization | 718.00K | 897.00K | 1.61M | 2.42M | 2.50M | 2.28M |
| Free cash flow | 68.97M | -61.36M | -116.77M | -119.51M | -132.26M | -139.93M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 80.02M | 41.72M | 212.40M |
| Ending cash balance | 30.66M | 145.02M | 63.96M | 69.81M | 72.10M | 114.85M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -41.70M | -36.52M | -30.95M | -29.72M | -44.36M | -38.87M |
| Depreciation & amortization | 622.00K | 625.00K | 555.00K | 479.00K | 463.00K | 425.00K |
| Free cash flow | -41.75M | -37.14M | -31.10M | -29.94M | -44.36M | -38.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 212.40M | 62.78M | 652.04M |
| Ending cash balance | 61.00M | 41.84M | 60.91M | 114.85M | 159.97M | 347.70M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -134.64 | -30.38 | -36.41 | -40.49 | -57.58 | -37.23 |
| ROA %i | -25.08 | -16.46 | -23.10 | -24.25 | -36.24 | -28.41 |
| ROIC %i | -112.04 | -29.84 | -34.31 | -36.61 | -51.58 | -34.83 |
| 5-year avg ROE %i | -- | -- | -- | -- | -59.90 | -40.42 |
| EBIT margin %i | -681.82 | -157.09 | -446.79 | -312.57 | -346.09 | -178.39 |
| FCF / sales %i | 900.84 | -- | -- | -- | -- | -- |
| Current ratioi | 4.73 | 12.10 | 6.76 | 7.54 | 6.98 | 16.32 |
| Quick ratioi | 4.70 | 11.97 | 6.63 | 7.33 | 6.76 | 15.83 |
| Debt / assetsi | 3.80 | 0.30 | 9.42 | 9.67 | 11.53 | 8.42 |
| LT debt / equityi | 17.94 | -- | 15.78 | 14.55 | 17.06 | 8.91 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 68.35 | 4.33 | 35.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -61.35 | -76.09 | -51.65 | -37.23 | -38.42 | -21.34 |
| ROA %i | -38.87 | -47.01 | -35.74 | -28.41 | -30.20 | -18.86 |
| ROIC %i | -54.39 | -66.03 | -45.41 | -34.83 | -36.12 | -21.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -355.87 | -647.37 | -165.91 | -178.39 | -206.22 | -253.38 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.26 | 4.75 | 8.88 | 16.32 | 27.38 | 50.82 |
| Quick ratioi | 6.03 | 4.52 | 8.29 | 15.83 | 26.51 | 49.95 |
| Debt / assetsi | 13.47 | 14.72 | 16.54 | 8.42 | 7.52 | 2.98 |
| LT debt / equityi | 20.46 | 24.06 | 19.78 | 8.91 | 7.65 | 2.84 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
United States100.00%
Quote time 2026-10-08 06:07:34 · For reference only, not investment advice and not tailored to your situation.